NSUN2 and hepatocellular carcinoma: That is, NSUN2 inhibits Ras signaling pathway activation and reduces the levels of Phospho-extracellular regulated protein kinases (p-ErK) in HCC, resulting in an increased sensitivity of HCC cells to sorafenib (Song et al., 2023).